These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 8244163

  • 41. Gynecological malignancies.
    Schaebler DL, Schilder RJ, Young RC.
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [Abstract] [Full Text] [Related]

  • 42. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience.
    Benjamin RS, Legha SS, Patel SR, Nicaise C.
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S174-9. PubMed ID: 8453693
    [Abstract] [Full Text] [Related]

  • 43. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 44. Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer.
    Fanning J, Hilgers RD.
    Gynecol Oncol; 1996 Dec; 63(3):323-7. PubMed ID: 8946866
    [Abstract] [Full Text] [Related]

  • 45. Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies.
    Hoffman PC, Masters GA, Drinkard LC, Krauss SA, Samuels BL, Golomb HM, Vokes EE.
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):11-5. PubMed ID: 8677441
    [Abstract] [Full Text] [Related]

  • 46. [Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl)].
    Burkert H, Schnitker J, Fichtner E.
    MMW Munch Med Wochenschr; 1979 Jun 01; 121(22):760-2. PubMed ID: 112422
    [Abstract] [Full Text] [Related]

  • 47. Gynecologic malignancies.
    Schilder RJ, Scher RM, Young RC.
    Cancer Chemother Biol Response Modif; 1993 Jun 01; 14():530-56. PubMed ID: 8312118
    [Abstract] [Full Text] [Related]

  • 48. Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders.
    Fukuoka M, Negoro S, Masuda N, Furuse K, Kawahara M, Kodama N, Ikegami H, Nakamura S, Nishio H, Ohnoshi T.
    J Cancer Res Clin Oncol; 1991 Jun 01; 117(5):473-8. PubMed ID: 1909700
    [Abstract] [Full Text] [Related]

  • 49. The role of ifosfamide in the treatment of testicular and urothelial malignancies.
    Roth BJ.
    Semin Oncol; 1996 Jun 01; 23(3 Suppl 7):19-27. PubMed ID: 8711497
    [Abstract] [Full Text] [Related]

  • 50. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
    Gershenson DM, Morris M, Burke TW, Levenback C, Wolf J, Lee JJ, Thall PF, Atkinson EN, Silva EG, Wharton JT.
    Cancer; 1999 Dec 01; 86(11):2291-300. PubMed ID: 10590370
    [Abstract] [Full Text] [Related]

  • 51. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS.
    Oncologist; 1996 Dec 01; 1(5):326-330. PubMed ID: 10388011
    [Abstract] [Full Text] [Related]

  • 52. Phase II trial of ifosfamide/mesna in metastatic adult renal carcinoma.
    De Forges A, Droz JP, Ghosn M, Theodore C.
    Cancer Treat Rep; 1987 Nov 01; 71(11):1103. PubMed ID: 3119203
    [No Abstract] [Full Text] [Related]

  • 53. The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience.
    Thigpen T, Vance RB, McGuire WP, Hoskins WJ, Brady M.
    Semin Oncol; 1995 Dec 01; 22(6 Suppl 14):23-31. PubMed ID: 8553080
    [Abstract] [Full Text] [Related]

  • 54. Ifosfamide in the treatment of malignant epithelial ovarian tumors.
    Lissoni AA, Fei F, Rossi R, Fruscio R, Villa A, Zani G.
    Oncology; 2003 Dec 01; 65 Suppl 2():59-62. PubMed ID: 14586150
    [Abstract] [Full Text] [Related]

  • 55. [Uroprotection with mesna in the chemotherapy of malignant tumors with oxazaphosphorines. Biometric evaluation of a sequential clinical study].
    Schnitker J.
    Arzneimittelforschung; 1982 Dec 01; 32(10):1334-8. PubMed ID: 6817761
    [Abstract] [Full Text] [Related]

  • 56. The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.
    Brock N.
    Recent Results Cancer Res; 1980 Dec 01; 74():270-8. PubMed ID: 6777836
    [Abstract] [Full Text] [Related]

  • 57. High-dose ifosfamide and mesna therapy in the outpatient setting.
    Heinzman K.
    J Intraven Nurs; 1992 Dec 01; 15(6):322-6. PubMed ID: 1484311
    [Abstract] [Full Text] [Related]

  • 58. Gynecologic Oncology Group studies with ifosfamide.
    Sutton GP, Blessing JA, Manetta A, Homesley H, McGuire W.
    Semin Oncol; 1992 Dec 01; 19(6 Suppl 12):31-4. PubMed ID: 1485172
    [Abstract] [Full Text] [Related]

  • 59. Ifosfamide--pharmacologic overview.
    Sarosy G.
    Semin Oncol; 1989 Feb 01; 16(1 Suppl 3):2-8. PubMed ID: 2649983
    [Abstract] [Full Text] [Related]

  • 60. Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.
    Falkson G, Van Dyk JJ, Stapelberg R, Falkson HC.
    Cancer Chemother Pharmacol; 1982 Feb 01; 9(2):81-4. PubMed ID: 6816479
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.